There is a strong focus on Genmab A/S (GMAB) stock, and the company has gained analyst support due to the successful sales of DARZALEX. Recent investments and buy ratings from companies like HC Wainwright and Deutsche Bank highlight the increasing interest in the stock. The company has also recently issued new Restricted Stock Units and Warrants to its employees. The acquisition of Merus N.V. by Genmab has given a significant boost to the company. The acquisition was completed via a tender offer for outstanding common shares and marked the commencement of a subsequent offering period. However, Genmab has also seen setbacks including shares dropping due to J&J's amivantamab data, and the discontinuation of acasunlimab development. Nevertheless, analysts at Truist Securities have raised their stock price target on Merus acquisition. On another positive note, the stock has shown very good performance levels with an increase of 8% following the royalty jump for DARZALEX and the success of Epcoritamab in Phase 3 trial. A partnership with Anthropic to use AI in drug research has also driven the stock's rise.
Genmab Stocks News Analytics from Mon, 02 Jun 2025 07:00:00 GMT to Sat, 14 Feb 2026 09:06:17 GMT - Rating 7 - Innovation 8 - Information 8 - Rumor -8
